China's CanSino Biologics Inc said on Wednesday its Covid-19 vaccine was approved in Mexico for emergency use for people of 18 years of age or older.
On Monday, Pakistan said CanSinoBio's vaccine showed 65.7% efficacy in preventing symptomatic cases and a 90.98% success rate in stopping severe disease in an interim analysis of global trials.
Mexico is one of the countries testing the vaccine and has a supply deal with company. It is also being tested in Russia, Argentina and Chile, clinical trial registration data showed.
The vaccine - which was approved for use in the Chinese military last year and has since been given to at least 40,000-50,000 people - uses a modified common cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus protein into the body.